次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

幹細胞技術と製品の世界市場2015-2025年

Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年12月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文262ページになります。
商品コード:VGN318

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
幹細胞(Stem Cells)の関連製品市場は全世界で2018年に120億ドル規模に達すると予測され、2015年から2025年にかけて高い成長を遂げると見込まれます。心筋梗塞、心不全、その他疾患における関連治療法は第III相臨床試験に達していることから、当レポート予測期間の今後10年間(2015-25)の途中より急成長を達成すると見込まれます。臨床段階の企業が、筋萎縮性側索硬化症(ALS)およびパーキンソン病のような中枢神経系(CNS)疾患に注力しているほか、加齢性黄斑変性症(AMD)などの眼症状にも取り組んでいます。関連治療法、治療機器、システムの将来性は強力であり、多くの市場機会が存在しているといえるでしょう。

【レポート概要】
・幹細胞関連製品の世界市場予測2015-2025年
・全262ページ、55個のデータ表、38個のチャート
<専門家オピニオンインタビュー>
- Mr Brock Reeve, Executive Director, Harvard Stem Cell Institute, Massachusetts, US
- Dr Mark Berman, Founder, Cell Surgical Network, US
- Dr Leonard Zon, Director of the Stem Cell Program at Children's Hospital Boston, Massachusetts, US
- Dr Artur Isaev, General Director, Human Stem Cells Institute, Moscow, Russia
- Dr Alan Trounson, Emeritus Professor, Monash University, Melbourne, Australia
- Dr Andras Nagy, Senior Scientist, Samuel Lunenfeld Research Institute, Mount Sinai Hospital

<治療分野別、市場予測2015-2025年>
• 癌、腫瘍VGN318_Stem Cell Technologies and Applications World Industry and Market Outlook 2015-2025 Cover.jpg
• 中枢神経系疾患
• 心血管疾患
• その他治療法
• 治療外用途

<製品別売上予測2015-2025年>
(※以下、主要6製品)
• Prochymal (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Elite and Evolution (Orthofix)
• Cartistem (Medipost).

<研究開発動向、市場の機会と課題(諸論点)>
• 米国、日本、欧州、韓国、中国、インド、イスラエルでの進展、当局規制、地域特色、展望
• 主要企業活動状況
(Mesoblast, Pharmicell, NuVasive, Orthofix, Medipost, Advanced Cell Technology, Athersys, Novartis, GSK and other organisations, private and public)
• 治療法と製品承認の拡大
• 日本における有望治療法の承認
• 再生医療、および糖尿病、肝臓変性、クローン病、慢性関節リウマチ、その他症状における使用
• 胚性幹細胞(ESC)、人工多能性幹細胞(iPS細胞)と単為生殖細胞
• 自家細胞 vs 同種異系細胞薬剤、ユニバーサル製品の可能性
• 造血幹細胞移植(HSCT)
• 臍帯血および関連技術における使用、細胞バンクを含む
• 希少疾病および難病治療
• 骨形成用薬剤、自己免疫疾患治療
• 細胞ベースアッセイ、診断、新薬開発向け製品

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025

Table of Contents

1. Report Overview

1.1 Global Stem Cell Technologies and Applications Market Overview
1.2 Global Stem Cell Technologies and Applications Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Stem Cell Technologies and Applications

2.1 What are Stem Cells?
2.2 Timeline of Stem Cell Research
2.2.1 Embryonic Stem Cells (ESCs) Enter the Picture
2.3 Classifying Stem Cells by Potency
2.3.1 Stem Cell Categories: ESCs, SSCs, IPSCs
2.3.2 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.3.3 Autologous versus Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.3.4 Advantages and Disadvantages of Different Cell Types
2.4 Regulation of Stem Cell Research
2.4.1 Regulation in the US
2.4.1.1 Understanding ‘Homologous Use’
2.4.1.2 Embryonic Stem Cell Research Remains Controversial
2.4.1.3 FDA v Regenerative Sciences: Regulating MSC Therapy
2.4.2 Regulation in Europe
2.4.2.1 The Brüstle Ruling: Dead and Buried?
2.4.2.2 The UK Leads in European Stem Cell R&D
2.4.3 Regulation in Japan
2.4.4 Regulation in Other Regions
2.4.4.1 South Korea Paves a Path for MSC Therapies
2.4.4.2 Liberal Chinese Laws for Stem Cell Research
2.4.4.3 Israel: A Strong Presence in Stem Cell Research
2.4.4.4 India: An Emerging Stem Cell Industry
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report

3. Stem Cell Technologies and Applications: World Market 2015-2025

3.1 The World Stem Cell Technologies and Applications Market in 2014
3.2 World Stem Cell Technologies and Applications Market: Regional Breakdown, 2014
3.3 Stem Cell Technologies and Applications Market Segmentation, 2014
3.4 Stem Cell Technologies and Applications Market: Sales Forecast 2015-2025
3.5 Stem Cell Technologies and Applications Market: Sales Forecast by Segment, 2015-2025
3.6 How Will Segmental Market Shares Change to 2025?
3.7 Non-Therapeutic Applications Lead the Stem Cell Technologies and Applications Market
3.8 Stem Cell Technologies and Applications Market: Drivers and Restraints 2015-2025
3.9 Recent Developments
3.9.1 STAP Cell Scandal in Japan
3.9.2 Tracheal Transplant Patient Dies
3.9.3 Stem Cell Rush in Japan after Regulatory Changes?

4. Stem Cell Cancer Therapeutics Segment 2015-2025

4.1 Stem Cell Cancer Therapeutics: Overview
4.2 The Stem Cell Cancer Therapeutics Market in 2014
4.3 Stem Cell Cancer Therapeutics: Market Forecast 2015-2025
4.4 Haematopoietic Stem Cell Transplantation (HSCT)
4.4.1 An Established Treatment for Haematological Cancers
4.4.2 Autologous HSCT Continues to Dominate
4.4.3 Allogeneic HSCT: More Rejections, Fewer Relapses
4.4.4 GvHD: The Major Issue for HSCT
4.4.5 Peripheral Blood: More Anti-Tumour Effect, More GvHD Risk
4.4.6 The Rise of Umbilical Cord Blood
4.4.7 80,000 HSCT Operations Performed Worldwide in 2014
4.4.8 HSCT Costly, Medicare Coverage Selective
4.4.9 Haematological Malignancies are the Major Indication for HSCT
4.4.10 HSCT Addresses Cancers Representing a $20bn Market
4.5 From Procedures to Products: Cord Blood Stem Cell Approvals
4.5.1 Hemacord (New York Blood Center)
4.5.2 HPC, Cord Blood (ClinImmune/University of Colorado Cord Blood Bank)
4.5.3 Ducord (Duke University School of Medicine)
4.5.4 Allocord (SSM Cardinal Glennon Children’s Medical Center)
4.5.5 HPC, Cord Blood BLA 125432 (LifeSouth Community Blood Centers)
4.6 Stem Cell Cancer Therapeutics: Pipeline Review 2015-2025
4.6.1 Apceth: Genetically Modified MSCs for Gastrointestinal Cancer
4.6.2 Athersys: MultiStem in Haematological Malignancies
4.6.3 Cellerant Therapeutics: CLT-008 and CLT-009
4.6.4 Cynata Therapeutics: Mass Producing MSCs for GvHD?
4.6.5 Fate Therapeutics: Modified HSCs for Haematological Malignancy
4.6.6 Gamida Cell: Shifting Focus from StemEx to NiCord
4.6.6.1 Survival at 100 Days Improved by StemEx in Latest Trial
4.6.6.2 NiCord Heads Up a Pipeline of Novel Cell Therapies
4.6.6.3 Novartis in Talks to Acquire Gamida Cell
4.6.7 ImmunoCellular Therapeutics: Stem Cells for Cancer Immunotherapy
4.6.8 Mesoblast: Using Mesenchymal Precursors to Enrich Cord Blood
4.6.8.1 Prochymal (remestemcel-L/MSC-100-IV, Mesoblast): Limited Market Access
4.6.8.2 The Development of Prochymal
4.6.8.3 Success in Subsets of GvHD Patients
4.6.8.4 An Important Role to Play in the Future of HSCT
4.6.8.5 Prochymal: Sales Forecast 2015-2025
4.6.8.6 Phase 3 Trial in Haematological Malignancies
4.6.8.7 A Competitor for Gamida Cell?
4.6.9 Novartis Developing Cord Blood Transplant Candidates
4.6.9.1 HSC835 Expanding Umbilical Cord Blood
4.6.9.2 Novartis Partners with Regenerex for Cell-Based Therapies
4.7 Other Stem Cell Oncology Prospects
4.7.1 Ancillary Products for the HSCT Setting
4.7.2 Targeting Cancer Stem Cells (CSCs)
4.7.3 Immunovative Therapies: Building on HSCT for a Cellular Anti-Cancer Therapy
4.8 Stem Cell Cancer Therapeutics: Drivers and Restraints 2015-2025

5. Stem Cell Cardiovascular Therapeutics Segment 2015-2025

5.1 Stem Cell Cardiovascular Therapeutics: Overview
5.2 The Stem Cell Cardiovascular Therapeutics Market in 2014
5.3 Stem Cell Cardiovascular Therapeutics: Market Forecast 2015-2025
5.4 Cardiovascular Diseases Dominate the Global Pharmaceutical Market
5.4.1 Cardiovascular and Cerebrovascular Conditions Are the World’s Most Fatal Diseases
5.4.2 AMI, CLI and Stroke: Major Ischaemic Disease Targets
5.5 The State of Stem Cell Research for Cardiovascular Diseases
5.5.1 Can Stem Cells Heal the Heart and Vasculature?
5.5.2 Stem Cell Treatments for Stroke
5.5.3 Defining Cardiovascular Stem Cells
5.6 Safety and Efficacy of MSCs in Clinical Trials
5.6.1 The Mysterious Efficacy of Adult Stem Cells in the Heart
5.6.2 Therapeutic Effects Despite Rapid Clearance
5.6.3 Doubts over the Efficacy of MSCs in the Heart
5.6.4 Looking Beyond MSCs
5.7 Stem Cell Cardiovascular Therapeutics in the Market
5.7.1 Pharmicell: Hearticellgram-AMI, One of the First Approved Cardiovascular Stem Cell Treatments
5.7.1.1 Hearticellgram-AMI Sales 2012-2013
5.7.1.2 Difficulty Accessing Markets Outside South Korea
5.7.1.3 Hearticellgram-AMI: Sales Forecast 2015-2025
5.7.1.4 Pharmicell: Pipeline Products
5.7.2 Reliance Life Sciences: CardioRel
5.8 Stem Cell Cardiovascular Therapeutics: Pipeline Review 2015-2025
5.8.1 Cytomedix Rebrands as Nuo Therapeutics, Exits Stem Cell R&D
5.8.2 Aastrom Biosciences (Vericel Corporation): Ixmyelocel-T
5.8.2.1 New Focus on Dilated Cardiomyopathy
5.8.3 Apceth: MSCs for Advanced Peripheral Vascular Disease
5.8.4 Arteriocyte: Nanex Technology to Treat CLI
5.8.5 Athersys: MultiStem in Stroke and Acute Myocardial Infarction
5.8.6 Baxter: Phase 3 in Refractory Angina
5.8.7 BioCardia: MSC Therapies for Heart Failure and AMI
5.8.8 Biogenea-Cellgenea: Still Developing Cardiogenea?
5.8.9 Bioheart: Phase 3 in Heart Failure, But Needs Extra Funding
5.8.9.1 Seeking Expanded Access for Compassionate Use
5.8.10 Capricor: Cardiosphere-Derived Cells for Heart Repair
5.8.11 Cardio3 BioSciences: Cardiopoiesis for Heart Regeneration
5.8.11.1 Phase 3 Trial Begins Amid Controversy
5.8.12 CellProthera: Myocardial Tissue Regeneration
5.8.13 Cytori Therapeutics: Stem Cells for Acute Myocardial Infarction
5.8.14 Human Stem Cells Institute: Developing Gemacell and Cryocell
5.8.15 Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
5.8.15.1 CEP-41750 Moving to Phase 3 in Congestive Heart Failure
5.8.15.2 Phase 2 in Acute Myocardial Infarction
5.8.15.3 Promising Preclinical Findings in Ischaemic Stroke
5.8.15.4 Teva Collaborating on Cardiovascular Stem Cell Therapy R&D
5.8.16 NeoStem: Diversified Outfit with One of the Leading Candidates
5.8.16.1 NBS10 to Treat Acute Myocardial Infarction
5.8.17 Stemedica Cell Technologies: Ischaemic-Tolerant Stem Cell Platform
5.8.17.1 Phase 2 in Acute Myocardial Infarction, Ischaemic Stroke, Heart Failure and Cutaneous Photoaging
5.8.18 Stempeutics: Emerging Indian Company Targets CLI
5.8.19 Other Stem Cell Cardiovascular Prospects
5.9 Can Stem Cells Change The Treatment Paradigm for Cardiovascular Disease?

6. Stem Cell Central Nervous System Therapeutics Segment 2015-2025

6.1 Stem Cell Central Nervous System Therapeutics: Overview
6.2 The Stem Cell Central Nervous System Therapeutics Market in 2014
6.3 Stem Cell Central Nervous System Therapeutics: Market Forecast 2015-2025
6.4 The State of Stem Cell Research in CNS Diseases
6.4.1 Stem Cells the Best Hope for Many Serious CNS Conditions
6.4.2 Awaiting a First Breakthrough Approval
6.4.3 Human NSCs Successfully Isolated
6.4.4 NSCs Reach the Clinic
6.4.5 CNS Disorders are the Major Focus for ESC Research
6.4.6 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
6.5 Progress in Specific CNS Conditions
6.5.1 HSCT in MS: Could ‘Resetting’ the Immune System Treat MS?
6.5.2 ALS: Rare Disease Could be the First Neurodegenerative Condition for Stem Cell Treatment
6.5.3 Parkinson’s Disease: Moratorium on Stem Cell Research Ends
6.5.4 Dry Age-Related Macular Degeneration: A Major Unmet Need
6.5.5 Several Multi-Billion Dollar Potential Markets in the Sights of CNS Stem Cell Developers
6.6 Stem Cell Central Nervous System Therapeutics: Pipeline Review 2015-2025
6.6.1 Advanced Cell Technology: Stem Cells for Eye Diseases
6.6.1.1 Stargardt’s Macular Degeneration: Moving to Phase 2
6.6.1.2 Early Signals of Efficacy, or Confounded Results?
6.6.1.3 Advancing to Phase 2 in Dry AMD
6.6.2 Athersys: Multistem for Ischaemic Stroke
6.6.3 BrainStorm Cell Therapeutics: Neurotrophic Factor-Releasing Stem Cells for ALS
6.6.3.1 Phase 2 Trial in 48 ALS Patients Underway
6.6.4 Cellonis Biotechnologies: Switching From Diabetes to Stroke
6.6.5 Corestem: MSCs for ALS
6.6.6 International Stem Cell Corporation: Preclinical CNS Treatments
6.6.7 InVivo Therapeutics: Neuro-Spinal Scaffold for Spinal Cord Injury
6.6.8 Mesoblast: Phase 2 in Wet AMD, Preclinical in Neurology
6.6.9Neuralstem: Allogeneic Neural Stem Cells for Synaptic Repair and Neuroprotection
6.6.9.1 Long-Term Follow-Up Data is Promising in ALS
6.6.9.2 Chronic and Acute Spinal Cord Injury Treatment to Follow
6.6.9.3 Ischaemic Stroke: Phase 1/2 Trials Underway in China
6.6.10 Preclinical Work in Other Neurological Disorders
6.6.11 NeuroGeneration: Investigating Human NSCs
6.6.12 Pfizer: Collaborating on the London Project to Cure Blindness
6.6.13 Q Therapeutics: Glial-Based Stem Cells as an ALS Treatment
6.6.14 ReNeuron: ReN001 is Demonstrating Potential in Stroke
6.6.14.1 Foetally-Sourced Cells Have Wide Potential Application
6.6.15 RhinoCyte: Stem Cells from the Nasal Passage to the Spinal Cord
6.6.16 SanBio: SB623 for Ischaemic Stroke
6.6.16.1 Future SanBio Programmes at Preclinical Stage in 2014
6.6.17 StemCells: a Leader in Neural Stem Cells
6.6.17.1 HuCNS-SC Product Proving Itself in Rare Indications
6.6.17.2 Moving on to Spinal Cord Injury and AMD
6.6.17.3 Alzheimer’s Disease and Stroke to Follow?
6.7 Other Companies with Technologies of Interest
6.7.1 iPierian – Bringing IPSCs to the CNS Market?
6.8 Stem Cell CNS Therapeutics: Drivers and Restraints 2015-2025

7. Stem Cell Therapeutics in Other Disease Areas 2015-2025

7.1 Stem Cell Therapeutics in Other Disease Areas: Overview
7.2 Stem Cell Therapeutics in Other Disease Areas: The Market in 2014
7.3 Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2015-2025
7.4 Stem Cell Therapeutics for Other Diseases in the Market
7.4.1 Osteocel Plus (NuVasive): The Leading Stem-Cell Orthobiologic
7.4.1.1 Osteocel to Osteocel Plus: A Chequered History
7.4.1.2 Better than Autograft?
7.4.1.3 Osteocel Plus: Sales Forecast 2015-2025
7.4.2 Trinity Elite and Evolution (Orthofix): Second-Generation Stem Cell Orthobiologics
7.4.2.1 Trinity Elite and Evolution: Sales Forecast 2015-2025
7.4.3 Cartistem (Medipost): ‘World’s First Allogeneic Stem Cell Drug’
7.4.3.1 Cartistem: Sales Forecast 2015-2025
7.4.4 LiquidGen (Skye Orthobiologics): Liquid Amniotic Allograft
7.4.5 AlloStem (Allosource)
7.4.6 Map3 (RTI Surgical)
7.5 Stem Cell Therapeutics for Other Diseases: Research Areas
7.5.1 HSCT for Orphan Diseases
7.5.2 Genetically Modified Stem Cells for HIV and Other Diseases
7.5.3 Stem Cells Are Osteogenic
7.5.4 Perianal Fistula Treatment Indicates Stem Cells’ Potential in Tissue Repair
7.5.5 Autoimmune Disorders Offer Real Market Potential
7.5.6 A Potential Cure for Diabetes?
7.5.7 Stem Cells in Active Liver Repair
7.5.8 Long-Range Possibilities
7.6 Stem Cell Therapeutics in Other Disease Areas: Pipeline Review 2015-2025
7.6.1 Alliancells Bioscience Corporation: Possible RA Treatment
7.6.2 AlloCure: AC607 Phase 2 Study Terminated
7.6.3 American CryoStem: ATCELL Preclinical Programmes
7.6.4 Anterogen: South Korean Stem Cell Company
7.6.5 Athersys: MultiStem Fails Phase 2 in Ulcerative Colitis
7.6.6 BioRestorative Therapies: Exploring Disc Disease and Diabetes
7.6.7 BioTime: Multiple Subsidiaries, Multiple Therapies
7.6.7.1 Asterias Biotherapeutics: Neurology and Oncology
7.6.7.2 Cell Cure Neurosciences: Phase 1/2a in Dry AMD
7.6.7.3 OncoCyte: Cancer Diagnostics
7.6.7.4 OrthoCyte: Orthopaedic Stem Cell Treatments
7.6.7.5 ReCyte: ESCs and IPSCs for Cardiovascular Diseases
7.6.7.6 Other BioTime Subsidiaries
7.6.8 Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
7.6.9 Celgene Cellular Therapeutics: Targeting Inflammatory Conditions
7.6.10 Cellular Biomedicine Group: MSCs for Knee Osteoarthritis
7.6.11 IntelliCell BioSciences: Adipose-Derived Stem Cells
7.6.12 Life Stem Genetics: Adipose-Derived Stem Cells
7.6.13 Medipost: Four Programmes in Development
7.6.14 Medistem: Acquired by Intrexon
7.6.15 Medistem Panama: Investigating MSCs
7.6.16 Mesoblast: MPCs for Crohn’s Disease, Diabetes and Rheumatoid Arthritis
7.6.16.1 Prochymal in Crohn’s Disease: Phase 3
7.6.16.2 Allogeneic MPCs for Diabetes in Phase 2
7.6.16.3 Allogeneic MPCs for Rheumatoid Arthritis in Phase 2
7.6.16.4 Allogeneic MPCs in Intervertebral Disc Repair and Spinal Fusion: Phase 2
7.6.17 Pluristem Therapeutics: Placental Stem Cells for Cardiovascular Diseases
7.6.18 Regeneus: Taking Adipose-Derived MSCs into Clinical Trials
7.6.19 S-Evans Biosciences: Menstrual Stem Cells for Hepatic Disease
7.6.20 TiGenix: Expanded Adipose-Derived Stem Cell Therapies
7.6.20.1 Cx601: Phase 3 Data Expected In July 2015
7.6.20.2 Cx611: Phase 2 in Rheumatoid Arthritis
7.6.20.3 Cx621: Intralymphatic Stem Cells for Autoimmune Diseases
7.6.20.4 ChondroCelect Already on the Market
7.6.21 ViaCyte: Revolutionising Diabetes Treatment with VC-01?
7.6.22 ViroMed: Genetically Modified Stem Cells for Chronic Granulomatous Disease
7.7 Genetically Modified Stem Cell Therapy Pipeline
7.7.1 Bluebird Bio: Gene-Modified HSCs for Orphan Diseases
7.7.2 GSK: Ex-Vivo Stem Cell Gene Therapies for Rare Diseases
7.7.3 Sangamo BioSciences: Genetically Modified Stem Cells for HIV

8. Stem Cell Non-Therapeutic Applications 2015-2025

8.1 Stem Cell Non-Therapeutic Applications: Overview
8.2 Stem Cell Non-Therapeutic Applications Market in 2014
8.3 Stem Cell Non-Therapeutic Applications: Market Forecast 2015-2025
8.4 Stem Cell Banking: Growing Demand Worldwide
8.4.1 Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
8.5 Stem Cell Supply and Processing: IPSCs the New Driver
8.6 Stem Cell-Based Assays: Major Potential for Preclinical Screens
8.7 Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
8.8 The Outlook for Non-Therapeutic Stem Cell Activities

9. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2015-2025

9.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
9.2 Strengths
9.2.1 HSCT is an Established Procedure
9.2.2 Recent Approvals of Stem Cell Therapies
9.2.3 Relaxation of Regulatory Barriers
9.3 Weaknesses
9.3.1 Uncertain Mechanism of Action in Stem Cell Therapies
9.3.2 Few Late-Stage Pipeline Products
9.3.3 Regulatory and Reimbursement Concerns
9.4 Opportunities
9.4.1 Genetic Modification of Stem Cells
9.4.2 Unmet Clinical Needs
9.4.3 Non-Therapeutic Uses: Cord Banking and Cell-Based Assays
9.4.4 Interactions with Related Technologies
9.5 Threats
9.5.1 Financial Risks
9.5.2 Pipeline Failure
9.5.3 Long-Term Safety Concerns
9.6 STEP Analysis of the Stem Cell Technologies and Applications Market
9.7 Social Factors
9.7.1 Increasing Burden of Disease
9.7.2 Biological Insurance through Stem Cell Banking
9.7.3 Stem Cell Tourism: the Hype and the Hope
9.8 Technological Factors
9.8.1 Increasing Research Output
9.8.2 IPSC Breakthroughs
9.8.3 Greater Understanding of Stem Cell Differentiation
9.8.4 Biomaterials, Bioprinting and Other Developments
9.8.5 CRISPRs: A Breakthrough in Genome Editing
9.9 Economic Factors
9.9.1 Grey Market for Stem Cell Therapies
9.9.2 Broad Changes in Pharma/Healthcare Markets
9.9.3 The Business Model Needs Further Development
9.10 Political Factors
9.10.1 Ethical Objections to Embryonic Stem Cell Research
9.10.2 Strong Support from National Governments
9.10.3 Pressure to Deregulate the Stem Cell Therapies Market

10. Research Interviews

10.1 Interview with Mr Brock Reeve, Executive Director, Harvard Stem Cell Institute, Massachusetts, US
10.1.1 Recent Developments in Stem Cells
10.1.2 Stem Cell Techniques and Therapies in 2015-2025
10.1.3 Potential Applications of Genome Editing
10.1.4 Therapeutic Areas for Stem Cell Therapies
10.1.5 The Need for New Business Models?
10.1.6 Developing the Stem Cell Therapy Market
10.1.7 Other Trends and Developments
10.2 Interview with Dr Mark Berman, Founder, Cell Surgical Network, US
10.2.1 Cell Surgical Network: Stem Cell Therapies
10.2.2 Cell Therapy as Investigative Treatment
10.2.3 Promising Therapeutic Applications
10.2.4 Future Developments for CSN and Stem Cell Therapies
10.2.5 The Need for New Business Models?
10.2.6 Regulatory Issues in Japan and Elsewhere
10.2.7 The FDA and Cell Surgical Network
10.2.8 Developing the Stem Cell Therapy Market
10.2.9 Other Trends and Developments
10.3 Interview with Dr Leonard Zon, Director of the Stem Cell Program at Children's Hospital Boston, Massachusetts, US
10.3.1 Recent Developments in Stem Cells
10.3.2 Research at Zon Laboratory
10.3.3 Stem Cell Techniques and Therapies in 2015-2025
10.3.4 The Need for New Business Models?
10.3.5 Developing the Stem Cell Therapy Market
10.3.6 Other Trends and Developments
10.4 Interview with Dr Artur Isaev, General Director, Human Stem Cells Institute, Moscow, Russia
10.4.1 Future Prospects for Cord Blood Stem Cell Banking
10.4.2 Increasing Competition in Stem Cell Banking
10.4.3 Progress with Gemacell and Cryocell
10.4.4 Opportunities in Russia and Other Markets
10.4.5 Challenges for Stem Cell Companies Over 2015-2025
10.4.6 Developing the Stem Cell Therapy Market
10.4.7 Other Trends and Developments
10.5 Interview with Dr Alan Trounson, Emeritus Professor, Monash University, Melbourne, Australia
10.5.1 Improved Funding in the Stem Cells Field
10.5.2 MSCs: Major Potential or Merely a Placeholder?
10.5.3 CIRM Investment Strategies
10.5.4 The Changing Regulatory Environment Worldwide
10.5.5 Key Trends for the Next Five to Ten Years
10.6 Interview with Dr Andras Nagy, Senior Scientist, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
10.6.1 Overview of the Current State of the IPSC Field
10.6.2 Genomic Stability and Other Potential Issues for IPSCs
10.6.3 Potential for Treating and Modelling Diseases with IPSCs
10.6.4 Reprogramming Without Transgenes
10.6.5 Possibilities for Directly-Converted Cells
11. Conclusions
11.1 Stem Cell Technologies and Applications: An Emerging Market
11.2 The Stem Cell Technologies and Applications Market in 2014
11.2.1 Current Leading Stem Cell Technologies and Applications Segments
11.2.2 Leading Regional Markets
11.3 World Stem Cell Technologies and Applications Market Forecast 2015-2025
11.4 Stem Cell Technologies and Applications Late-Stage Pipeline
11.5 The Future of the Stem Cell Technologies and Applications Market
11.5.1 Challenges for the Stem Cells Market
11.5.2 Concluding Remarks

List of Tables

Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs, 2014
Table 2.3 Main Types of Stem Cells and Their Properties, 2014
Table 2.4 Stem Cell Donor Terminology, 2014
Table 2.5 NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2014
Table 2.6 Clinical Trial Phases
Table 2.7 Currency Exchange Rates, 2013 and 2014
Table 3.1 Stem Cell Technologies and Applications Market by Region: Revenue ($m), Market Share (%), 2014
Table 3.2 Stem Cell Technologies and Applications Market by Segment: Revenue ($m), Market Share (%), 2014
Table 3.3 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 3.4 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2014-2019
Table 3.5 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2020-2025
Table 3.6 Stem Cell Technologies and Applications Market by Segment: Revenue ($m), Market Share (%), 2019 and 2025
Table 4.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.2 Comparison of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2014
Table 4.3 Global HSCT Operations: Estimated Number of Operations by Donor Type, 2012-2014
Table 4.4 European HSCT Operations: Number of Operations by Donor Type, 2003-2012
Table 4.5 Indications with Medicare Coverage for HSCT, 2014
Table 4.6 Malignancies and Other Haematological Diseases Treated with HSCT, 2014
Table 4.7 HSCT-Addressable Cancers: Estimated Incidence in the Major Markets (Number of Cases), CAGR (%), 2012-2024
Table 4.8 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2014
Table 4.9 Stem Cell Cancer Therapeutics Pipeline, 2014
Table 4.10 Mesoblast: Prochymal Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.2 Global Cardiovascular Disease Market by Drug Class: Revenue ($bn), 2014
Table 5.3 Projected Global Deaths From Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
Table 5.4 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), 2012-2013
Table 5.5 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 Reliance Life Sciences: CardioRel Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.7 Stem Cell Cardiovascular Therapeutics: Phase 2 and Phase 3 Pipeline, 2014
Table 5.8 Stem Cell Cardiovascular Therapeutics: Preclinical and Phase 1 and 1/2 Pipeline, 2014
Table 6.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 6.2 Stem Cell CNS Therapeutics: Phase 2 and 3 Pipeline, 2014
Table 6.3 Stem Cell CNS Therapeutics: Phase 1 and 1/2 Pipeline, 2014
Table 6.4 Stem Cell CNS Therapeutics: Preclinical Pipeline, 2014
Table 7.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 7.2 Selected Currently Available Stem Cell Therapeutics for Other Diseases, 2014
Table 7.3 NuVasive: Osteocel Plus Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.4 Orthofix: Trinity Elite and Evolution Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.5 Medipost: Cartistem Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.6 Diseases Other than Cancers to be Treated with HSCT, 2014
Table 7.7 Processes and Mechanism of Bone Repair, 2014
Table 7.8 Stem Cell Therapeutics in Other Diseases: Phase 2 and 3 Pipeline, 2014
Table 7.9 Stem Cell Therapeutics in Other Diseases: Phase 1 and 1/2 Pipeline, 2014
Table 7.10 Stem Cell Therapeutics in Other Diseases: Preclinical Pipeline, 2014
Table 7.11 Selected Genetically Modified Stem Cell Therapies Pipeline, 2014
Table 8.1 Stem Cell Non-Therapeutic Applications Market by Activity: Revenue ($m), Market Share (%), 2014
Table 8.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 8.3 Selected US Stem Cell Banks, 2014
Table 8.4 Selected Non-US Stem Cell Banks, 2014
Table 8.5 Selected Stem Cell Supply and Processing Companies, 2014
Table 8.6 Selected Companies With Involvement in Stem Cell-Based Assays, 2014
Table 8.7 Selected Companies With Other Stem Cell-Related Activities, 2014
Table 9.1 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2014-2025
Table 11.1 Stem Cell Therapy Late-Stage Pipeline, 2014

List of Figures

Figure 1.1 Estimated Numbers of European HSCT Operations, 2003-2014
Figure 1.2 Global Stem Cell Technologies and Applications Market Segmentation Overview, 2014
Figure 2.1 Timeline of Stem Cell Research, 1900-2014
Figure 3.1 Stem Cell Technologies and Applications Market: Market Shares (%) of Therapeutic and Non-Therapeutic Applications, 2014
Figure 3.2 Stem Cell Technologies and Applications Market: Market Share (%) by Region, 2014
Figure 3.3 Stem Cell Technologies and Applications Market by Segment: Market Share (%), 2014
Figure 3.4 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 3.5 Stem Cell Technologies and Applications Market Forecast: Revenues ($m) by Segment, 2014-2025
Figure 3.6 Stem Cell Technologies and Applications Market: Market Share (%) by Segment, 2019
Figure 3.7 Stem Cell Technologies and Applications Market: Market Share (%) by Segment, 2025
Figure 3.8 Stem Cell Technologies and Applications Market: Drivers and Restraints, 2015-2025
Figure 4.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.2 Global HSCT Operations by Donor Type, 2014
Figure 4.3 European HSCT Operations by Donor Type, 2003-2012
Figure 4.4 HSCT-Addressable Cancers: Estimated Incidence in the Major Markets (Number of Cases), 2012-2024
Figure 4.5 Mesoblast: Prochymal Revenue ($m), AGR (%), 2014-2025
Figure 4.6 Stem Cell Cancer Therapeutics Market: Drivers and Restraints, 2015-2025
Figure 5.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%),2014-2025
Figure 5.2 Global Cardiovascular Disease Market by Drug Class: Market Share (%), 2014
Figure 5.3 Projected Global Deaths From Ischaemic Heart Disease and Stroke (millions), 2015 and 2030
Figure 5.4 Pharmicell: Hearticellgram-AMI Revenue ($m), 2012-2013
Figure 5.5 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), 2014-2025
Figure 5.6 Reliance Life Sciences: CardioRel Revenue ($m), AGR (%), 2014-2025
Figure 5.7 Stem Cell Cardiovascular Therapeutics Market: Drivers and Restraints, 2015-2025
Figure 6.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.2 Stem Cell CNS Therapeutics Market: Drivers and Restraints, 2015-2025
Figure 7.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 7.2 NuVasive: Osteocel Plus Revenue ($m), AGR (%), 2014-2025
Figure 7.3 Orthofix: Trinity Elite and Evolution Revenue ($m), AGR (%), 2014-2025
Figure 7.4 Medipost: Cartistem Revenue ($m), AGR (%), 2014-2025
Figure 8.1 Stem Cell Non-Therapeutic Applications Market by Activity: Market Share (%), 2014
Figure 8.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 8.3 Stem Cell Non-Therapeutic Applications Market: Drivers and Restraints, 2015-2025
Figure 9.1 Stem Cell Technologies and Applications Market: Strengths and Weaknesses, 2015-2025
Figure 9.2 Stem Cell Technologies and Applications Market: Opportunities and Threats, 2015-2025
Figure 9.3 Stem Cell Technologies and Applications Market: STEP Analysis, 2015-2025
Figure 9.4 World 65+ Population Forecast: Size (m), AGR (%), 2014-2025
Figure 11.1 Stem Cell Technologies and Applications Market Forecast: Revenues ($m) by Therapeutic and Non-Therapeutic Applications, 2014-2025

掲載企業リスト

Companies Listed

3-D Matrix
Adistem
Advanced Cell Technology
Ageless Regenerative Institute
Aldagen
Alder Biopharmaceuticals
Alkems
AllCells
Allergan
Alliancells Bioscience Corporation (subsidiary of Zhongyuan Union Stem Cell Bio-engineering)
AlloCure
Allosource
ALS Association
American Academy of Pediatrics (AAP)
American Board of Cosmetic Surgery
American Board of Otolaryngology/head and Neck Surgery
American College of Surgeons
American CryoStem
American Society of Blood and Marrow Transplantation
Americas Committee for Treatment and Research in Multiple Sclerosis
Americord
Amgen
Amorcyte
AngioCrine Bioscience
Angiotech Pharmaceuticals
Anterogen (subsidiary of Bukwang Pharm Co Ltd)
Antria
apceth
Aristotle University of Thessaloniki
Arteriocyte
Asterias Biotherapeutics (subsidiary of BioTime)
Athersys
Autogenesis
Axiogenesis
Baxter International
BaYi Brain Hospital (China)
Beike Biotechnology
Berkshire Hathaway
Beth Israel Deaconess Medical Center
BioCardia
BioE
BioEden
Biogen Idec
Biogenea-Cellgenea
Bioheart
Biologic Therapies
Biomatrica
Biomet
BioRestorative Therapies
Biotec Services International
BioTime
BioTime Asia (subsidiary of BioTime)
Blackstone Medical (acquired by Orthofix)
bluebird bio
Boston Children's Hospital
BrainStorm Cell Therapeutics
Bukwang Pharm Co Ltd
California Institute of Regenerative Medicine (CIRM)
California Institute of Technology (Caltech)
Calimmune
Cancer Research UK / Cancer Research Technology
Capricor
Cardio3 BioSciences
Cardiogenesis
Carolinas Cord Blood Bank
Casey Eye Institute, Oregon Health and Science University
Cedars-Sinai Heart Institute
Celgene
Celgene Cellular Therapeutics (formerly Anthrogenesis; subsidiary of Celgene)
Cell Cure Neurosciences (subsidiary of BioTime)
Cell Surgical Network
Cell Targeting (assets acquired by BioTime)
Cell Therapy Limited
Cellartis (subsidiary of Takara Bio)
CellCentric
Cellectis
Cellerant Therapeutics
Cellerix (merged with TiGenix)
Cellonis Biotechnologies
CellProthera
CellSeed
Cellular Biomedicine Group
Cellular Dynamics International (CDI)
Center for International Blood and Marrow Transplant Research (CIBMTR)
Centers for Medicare & Medicaid Services (CMS)
Cephalon (part of Teva)
Cesca Therapeutics
CHA Biotech
Cha General Hospital (Seoul, South Korea)
Chicago Medical School
China Cord Blood Corporation
Chinese Academy of Sciences
Cipla
CJ CheilJedang
Cleveland Biolabs
ClinImmune Labs
Cognate BioServices
Consortium of Multiple Sclerosis Centers
Cook General BioTechnology
Cord Blood America
Cord Blood Registry Systems
Cordlife Group
CoreStem
CRISPR Therapeutics
Cryo-Cell International
CryoCord
Cryonix CJSC
Cryo-Save
CryoSite
CXR Biosciences
Cynata Therapeutics (formerly Eco Quest Ltd)
Cytori Therapeutics
Dendreon
Department of Biotechnology (India)
Dong-A Pharmaceuticals Co. (South Korea)
Duke University
Eli Lilly
EpiStem
ES Cell International (subsidiary of BioTime)
ESI BIO (subsidiary of BioTime)
European Group for Blood and Marrow Transplantation (EBMT)
European Haematology Association
European Medicines Agency (EMA)
Fate Therapeutics
FDS Pharma
Fondazione Centro San Raffaele
Fondazione Telethon
Forbion Capital Partners
Forticell Bioscience
Gamida Cell
Gemabank (Human Stem Cells Institute cord blood bank)
Genetrix Group
Genomics Institute, Novartis Research Foundation
Genzyme (part of Sanofi)
Geron Corporation
Gilead Sciences
GlobalStem
Globocan
GMP Unlimited
Grey Innovation
GSK
Hadassah Medical Center
Harvard Apparatus Regenerative Technology
Harvard Business School
Harvard Stem Cell Institute
Harvard University
Health Canada
Human Fertilisation and Embryology Authority (HFEA) (UK)
Human Stem Cells Institute (Russia)
ImmunoCellular Therapeutics
Immunovative Therapies
Insception Biosciences
Institute of Biomedical Research (Japan)
IntelliCell Biosciences
International Society for Stem Cell Research (ISSCR)
International Stem Cell Corporation (ISCO)
International Stemcell Services
Intrexon Corporation
Invivo Therapeutics
IPS Academia Japan
IRCCS San Raffaele Hospital
Israel Stem Cell Society
JCR Pharmaceuticals
Johann Wolfgang Goethe University Hospital
Johnson & Johnson
Karolinska Institute
Kreos Capital
Life Stem Genetics
Lifebank Cryogenics
LifebankUSA
LifeMap Sciences (subsidiary of BioTime)
LifeMap Solutions (owned by Lifemap Sciences)
LifeSouth Community Blood Centers
Lincoln Park Capital
Lonza
Massachusetts General Hospital
Maxcyte
Mayo Clinic
McLean Hospital
MedCell Bioscience
Medical Protective Company
Medicines and Healthcare Products Regulatory Agency (MHRA) (UK)
Medipost
Medistem (formerly Medistem Laboratories; acquired by Intrexon)
Medistem Panama
Medpace Inc.
Medtronic
Merck & Co.
Merck Millipore
Mesoblast
MetaCyte Business Lab
Miltenyi Biotec
Ministry of Economy, Trade and Industry (Japan)
Ministry of Food and Drug Safety (MFDS) (South Korea)
Ministry of Health (China)
Ministry of Science and Technology (China)
Monash University
Mount Sinai Hospital
Musculoskeletal Transplant Foundation
National Dental Pulp Laboratory (subsidiary of New England Cryogenic Center)
NeoStem
NeuralStem
NeuroGeneration
NeuroSearch
New England Cryogenic Center
New York Blood Center
New York Heart Association
Nippon Zoki Pharmaceutical
Northern Therapeutics
Novartis
NsGene
Nuo Therapeutics (formerly Cytomedix)
NuVasive
OncoCyte (subsidiary of BioTime)
Opexa Therapeutics
OrbusNeich
OrthoCyte (subsidiary of BioTime)
Orthofix
Osiris Therapeutics
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmicell (formerly FCB-Pharmicell)
Pharmsynthez
Plasticell
Pluristem
Polyphor
Proneuron Biotechnologies
Q Therapeutics
Queen Mary University of London
Quest Biomedical
Recyte Therapeutics (subsidiary of BioTime)
Regenerative Medicine Institute of Tijuana
Regenerative Sciences
Regenerex
Regenetech
Regeneus
Reliance Life Sciences
ReNeuron
Renovo Neural
RenovoCyte (subsidiary of Cook General BioTechnology)
RepliCel Life Sciences
ReproCELL
RhinoCyte
RIKEN Center for Developmental Biology
Roche
Roslin Cellab
RTI Surgical
RUSNANO
Rutgers University
Samuel Lunenfeld Research Institute
San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)
SanBio
Saneron CCEL Therapeutics
Sanofi
Sao Paolo University Hospital
Schepens Eye Research Institute
S-Evans Biosciences
Singapore National Eye Centre
Sirna Therapeutics
Skye Orthobiologics
Society for Neuroscience
Spinesmith Partners
SSM Cardinal Glennon Children's Medical Center
St. Louis Cord Blood Bank
Stamina Foundation
Stem Cell Therapeutics
Stemcell Technologies
StemCells
StemCore
StemCyte
Stemedica Cell Technologies
StemGen
Stemina Biomarker Discovery
Stempeutics
SynBio (joint venture)
Takara Bio
TAP Biosystems (Sartorius Stedim Biotech)
Targazyme (formerly America Stem Cell)
Tel Aviv University
Teva
Texas Medical Board
Therapeutic Goods Administration (TGA) (Australia)
Theratechnologies
Tianhe Stem Cell Biotechnologies
TiGenix
Tong Yuan Stem Cell
TrakCel
Translational Biosciences (subsidiary of Medistem Panama)
UHV Technologies
UK Medical Research Council
uniQure
University College London
University of California San Francisco
University of Colorado
University of Heidelberg
University of Kyoto
University of Massachusetts
University of Miami
University of Milan
University of Minnesota
University of Washington
University of Wisconsin
Uppsala University Hospital
US Food and Drug Administration (FDA)
US National Institute of Allergy and Infectious Diseases (NIAID)
US National Institutes of Health (NIH)
US National Marrow Donor Program
US Patent and Trademark Office
Valeant
Vericel Corporation (formerly Aastrom Biosciences)
Vesta Therapeutics
ViaCord
ViaCyte (formerly NovoCell)
ViroMed Laboratories
Vitro Biopharma
WA Optimum Health Care
World Health Organization
Yale University
Yonsei University
Zhongyuan Union Stem Cell Bio-engineering

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

関連レポート紹介

幹細胞技術のリーデイング企業2014-2024年

幹細胞技術のリーディング企業22社を特定し、その技術、業績、トレンド、市場機会、収益予測など2014年以降の展望、および同技術の世界市場予測を概略以下の構成でお届けしています。

レポートページへLinkIcon

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。